NASDAQ:KALV - Kalvista Pharmaceuticals Stock Price, Forecast & News

Kalvista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KALV shares have decreased by 16.1% and is now trading at $7.43. View which stocks have been mosted impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, July 20th 2020. View our earnings forecast for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) posted its quarterly earnings results on Tuesday, March, 10th. The specialty pharmaceutical company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.26. The specialty pharmaceutical company had revenue of $1.58 million for the quarter, compared to the consensus estimate of $3.30 million. Kalvista Pharmaceuticals had a negative return on equity of 32.17% and a negative net margin of 263.38%. View Kalvista Pharmaceuticals' earnings history.

3 Wall Street analysts have issued twelve-month price objectives for Kalvista Pharmaceuticals' stock. Their forecasts range from $28.00 to $31.00. On average, they expect Kalvista Pharmaceuticals' share price to reach $29.67 in the next year. This suggests a possible upside of 299.3% from the stock's current price. View analysts' price targets for Kalvista Pharmaceuticals.

Media headlines about KALV stock have trended very negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kalvista Pharmaceuticals earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutKalvista Pharmaceuticals.

Some companies that are related to Kalvista Pharmaceuticals include Assembly Biosciences (ASMB), ZIOPHARM Oncology (ZIOP), RAPT Therapeutics (RAPT), Frequency Therapeutics (FREQ), Sinovac Biotech (SVA), ANI Pharmaceuticals (ANIP), DiaMedica Therapeutics (DMCAF), Provention Bio (PRVB), Prothena (PRTA), Emisphere Technologies (EMIS), Clovis Oncology (CLVS), Morphic (MORF), Neoleukin Therapeutics (NLTX), BioXcel Therapeutics (BTAI) and Kura Oncology (KURA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Viking Therapeutics (VKTX), Ritter Pharmaceuticals (RTTR), Agile Therapeutics (AGRX), Amarin (AMRN) and Anavex Life Sciences (AVXL).

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KALV stock can currently be purchased for approximately $7.43.

Kalvista Pharmaceuticals has a market capitalization of $132.63 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe. View additional information about Kalvista Pharmaceuticals.

The official website for Kalvista Pharmaceuticals is http://www.kalvista.com/.

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]